Hexokinase 2 Is a Pivot for Lovastatin-induced Glycolysis-to-Autophagy Reprogramming in Triple-Negative Breast Cancer Cells
Lian Xue, Mi Wu, Ying Li, Sisi Chen, Muyao Wu, Jianyu Zhu, Siyu Ding, Qiuting Zhang, Chanjuan Zheng, Guangchun He, Shujun Fu, Guifei Li, Xiyun Deng · Journal of Cancer · 2022
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2022
Abstract
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with limited therapeutic options available.We have recently demonstrated that lovastatin, a 3-hydroxy-3methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, suppresses TNBC cell proliferation and stemness properties in vitro and in vivo.However, the mechanisms through which lovastatin inhibits TNBC cells are not fully understood.Here, we used 1 H NMR-based metabolomic profiling to investigate lovastatin-induced metabolic changes in TNBC cell line MDA-MB-231.Among the 46 metabolites identified, lactate demonstrated the highest variable importance in projection (VIP) score.Glycolysis stress test revealed that lovastatin significantly decreased the extracellular acidification rate (ECAR) in MDA-MB-231 cells.Furthermore, lovastatin treatment down-regulated the levels of glycolysis-related proteins including GLUT1, PFK1, and PKM2 in MDA-MB-231 but not non-TNBC MDA-MB-453 cells.In addition, lovastatin induced autophagy as evidenced by increased LC3 puncta formation and LC3-II/I ratio, increased AMPK phosphorylation, and decreased Akt phosphorylation.We also revealed the interaction between the glycolytic enzyme hexokinase 2 (HK2) and the mitochondrial membrane protein voltage-dependent anion channel 1 (VDAC1), an important regulator of autophagy.Further bioinformatics analysis revealed that VDAC1 was expressed at a higher level in breast cancer than normal tissues and higher level of VDAC1 predicted poorer survival outcomes in breast cancer patients.The present study suggests that lovastatin might exert anti-tumor activity by reprogramming glycolysis toward autophagy in TNBC cells through HK2-VDAC1 interaction.
Open the resolved locator · 10.7150/jca.71592
Metadata licence: OpenAlex metadata (CC0)